Zhuhai holds the academic activity of the standardized diagnosis and treatment of the bottom of the eye

Text, Figure/Yangcheng Evening News all -media reporter Qin Xiaojie (except the picture signature)

On August 14th, under the guidance of the Zhuhai Market Supervision and Administration Bureau, hosted by the Guangdong Medical Industry Association, Hong Kong Hima International Ophthalm Medical Group, and hosted by the "Eye Innovation Drug Standardized Diagnosis and Treatment Academic Activities and Boxi Zhu Ximu Shanzhu Shan The establishment ceremony of anti -innovation drug clinical practice expert consultant group "was held in Zhuhai. In this event, more than 40 ophthalmological experts are invited to link online and offline to build a communication platform for colleagues of ophthalmology to contribute wisdom and strength to the promotion of the standardized diagnosis and treatment of the bottom of the eye.

Activity sign -in table

Empower the diagnosis and treatment of the bottom of the eyes

Innovative drug clinical practice expert group was established

The expert consultant group of the Baxi Shan Anti -innovation drug clinical practice was jointly initiated by Professor Xu Xun, Professor Xu Xun, the First People's Hospital of Shanghai Jiaotong University, Professor Lin Shunchao, Hima International Ophthalm Medical Group, Hong Kong, and Professor Lin Xiaofeng, Sun Yat -sen University of Sun Yat -sen University. Thanks to the support of the "Hong Kong and Macau Medicine Division" policy, the innovative drugs of the bottom of the eyes can be applied in the Mainland, bringing new hopes for patients with bottom diseases in the country. Professor Xu Xun said that we hope to consolidate a group of influential experts across the country and strengthen cooperation to accumulate clinical experience, so as to accelerate the construction of the standardized diagnosis and treatment system of the bottom of the eye.

It is understood that the consultant group of the clinical practice experts of Boxing Single Anti -innovation drugs invites clinical experience and influential ophthalmologists to join in order to build a platform that integrates high -quality service patients, academic exchanges and clinical practice to jointly promote the introduction of Hong Kong and Macau in China The further development of innovative drugs is empowering the field of eye disease in China.

Figures of the Expert Consultant Corps set up an interviewee

The Boxest Single is developed by Novartis Group for the treatment of wet age -related macular degeneration (WAMD) and diabetic macular edema (DME). Compared with existing treatment methods Line, continuously improved the anatomical structure and other aspects of anatomical structure every 3 months. The implementation of Baxitabi at the Shimarin Ophthalmology Hospital of Zhuhai can further reduce the harm of blind eye disease and benefit more patients.

Participating experts discussed warmly

Focus on the academic frontier of the eye disease

Continue to promote standardized diagnosis and treatment

In academic lectures and theme discussions, ophthalmology experts focus on the advancement of the cutting -edge progress and clinical experience of the innovative drugs of the eyes, and the standardized topics such as the standardized diagnosis and treatment of the bottom of the eye.

Professor Chen Qingshan, Shenzhen Eye Hospital affiliated to Jinan University, said that the effusion of NAMD is pathological. Elimination of early effusion is of great significance for anatomy and vision recovery. At the same time The Boxi Ming Mippot compared to the control group earlier, and control the effusion smoothly and lasting; the Baxitabi Mipide helps reduce the number of treatment times and reduce the treatment burden of patients. Professor Chen Youxin, Beijing Union Hospital, introduced the Bixing Ming Da Bay Area project and explained the direction of the clinical practice of the bottom of the eyes.

Professor Lin Shunchao, Hong Kong Hima International Ophthalm Medical Group, brought the "Boxing Midticoper's 100 Plan China", stating that the project was led by the expert consultant group of the clinical practice of Anti -innovation drugs, and actively improved with the concept of openness. The use of new drugs is available. By establishing the Boxing Ming Mingist operation manual and standardizing the use of consensus, the development of the underground vehicle project of the Greater Bay Area, the establishment of clinical case sharing, and an academic exchange platform, it ultimately benefits more patients.

It is reported that the Daowan District Eye Direct Linking Project is expected to cover 100 patients, providing each patient with a 6 -stitched price injection benefit subsidy of the Boxi Ming Ming, and the Green Channel of the Shimalin Ophthalmology Hospital in Zhuhai. Patients with fundus diseases create a one -stop standardized diagnosis and treatment model to help patients reduce the economic burden in treatment. At the same time, it can also help the bottom of the eye doctors to accumulate new drug use experience and promote the standardized diagnosis and treatment in the field of innovative drugs in China.

During the academic discussion session, experts conducted in -depth discussions on the "most suitable patients with the most suitable patient, how to achieve better follow -up and clinical monitoring of patients with innovative drugs, how to achieve real world results transformation" , Explore solutions and plans and reach preliminary consensus, and hope to create a more convenient, efficient and worry -free diagnosis and treatment process to jointly improve the current status of the treatment of patients with the bottom of the eyes.

It is understood that in January 2022, the National Health Commission released the "Fourteenth Five-Year Plan" National Eye Health Plan (2021-2025) ", marking that my country's eye health work has entered a new stage of high-quality development. For the first time, the "Planning" included the bottom disease in the core disease and rose to the national strategy, which gave very high attention.

Eye disease is the main blind eye disease in my country

Data show that there are currently more than 30 million patients with various types of eye disease diseases in my country, and fundus disease has become the main blind eye disease in China; in my country, more than 3 million patients with eye diseases have been added to the hospital for diagnosis and treatment, but the correct treatment rate is less than 10 10 10 %.The late eye disease is easy to cause irreversible vision and vision damage. The existing diagnosis and treatment methods cannot fully meet the patient's diagnosis and treatment needs. Numerous patients and their families are expected to be innovative drugs in the eyes.The diagnosis and treatment collaboration network, promote the standardization and popularization of the diagnosis and treatment of the bottom of the eye, and jointly improve the current status of the treatment of Chinese ophthalmic patients. It has become the focus of attention in the medical field.Source | Yangcheng Evening News · Yangcheng School

Responsible | Yellow Tie'an

School Delivery | Zhao Dandan

- END -